These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35801760)

  • 21. Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis.
    Qiu Y; Mao R; Chen BL; Zhang SH; Guo J; He Y; Zeng ZR; Ben-Horin S; Chen MH
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1359-1372.e6. PubMed ID: 28232073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic Review and Meta-Analysis of Inflammatory Bowel Disease Adverse Events with Anti-Interleukin 17A Agents and Tumor Necrosis Factor Inhibitors in Rheumatic Disease and Skin Psoriasis.
    Truong SL; Chin J; Liew DFL; Zahir SF; Ryan EG; Rubel D; Radford-Smith G; Robinson PC
    Rheumatol Ther; 2021 Dec; 8(4):1603-1616. PubMed ID: 34449067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents.
    Karmiris K; Bossuyt P; Sorrentino D; Moreels T; Scarcelli A; Legido J; Dotan I; Naismith GD; Jussila A; Preiss JC; Kruis W; Li AC; Bouguen G; Yanai H; Steinwurz F; Katsanos KH; Subramaniam K; Tarabar D; Zaganas IV; Ben-Horin S;
    J Crohns Colitis; 2015 May; 9(5):382-9. PubMed ID: 25740813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis.
    Esse S; Mason KJ; Green AC; Warren RB
    JAMA Dermatol; 2020 Jul; 156(7):787-794. PubMed ID: 32432649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Course of Very Early-Onset Inflammatory Bowel Disease.
    Cucinotta U; Arrigo S; Dipasquale V; Gramaglia SMC; Laganà F; Romano C; Gandullia P
    J Pediatr Gastroenterol Nutr; 2023 May; 76(5):590-595. PubMed ID: 36754082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An Assessment of Comparative Medication Durability in Inflammatory Bowel Disease Patients With and Without Co-morbid Psoriasis, Rheumatoid Arthritis, and/or Enteropathic Arthritis.
    Cushing K; Gudjonsson JE; Speliotes E; Higgins PDR
    Dig Dis Sci; 2023 Oct; 68(10):4001-4008. PubMed ID: 37555882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
    Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
    Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic Predictors of Long-term Response to Antitumor Necrosis Factor Agents in Pediatric Inflammatory Bowel Disease.
    Salvador-Martín S; Bossacoma F; Pujol-Muncunill G; Navas-López VM; Gallego-Fernández C; Viada J; Muñoz-Codoceo R; Magallares L; Martínez-Ojinaga E; Moreno-Álvarez A; Solar-Boga A; Segarra O; Clemente S; Rodriguez-Martinez A; Alvarez-Vayo C; Loverdos I; Merino-Bohórquez V; Balboa-Vega MJ; Blanca-García JA; Fobelo MJ; Millán-Jiménez A; García-Romero R; Sanchez C; Tolín M; Caldas RG; Eizaguirre FJ; Sánchez-Hernandez JG; Torres-Peral R; Aznal E; García-González X; Sanjurjo-Sáez M; López-Fernández LA
    J Pediatr Gastroenterol Nutr; 2020 Oct; 71(4):508-515. PubMed ID: 32773718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
    Aardoom MA; Veereman G; de Ridder L
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study.
    Guerra I; Pérez-Jeldres T; Iborra M; Algaba A; Monfort D; Calvet X; Chaparro M; Mañosa M; Hinojosa E; Minguez M; Ortiz de Zarate J; Márquez L; Prieto V; García-Sánchez V; Guardiola J; Rodriguez GE; Martín-Arranz MD; García-Tercero I; Sicilia B; Masedo Á; Lorente R; Rivero M; Fernández-Salazar L; Gutiérrez A; Van Domselaar M; López-SanRomán A; Ber Y; García-Sepulcre M; Ramos L; Bermejo F; Gisbert JP;
    Inflamm Bowel Dis; 2016 Apr; 22(4):894-901. PubMed ID: 26933750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Psoriasis With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    Fu Y; Lee CH; Chi CC
    JAMA Dermatol; 2018 Dec; 154(12):1417-1423. PubMed ID: 30422277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pretreatment Frailty Is Independently Associated With Increased Risk of Infections After Immunosuppression in Patients With Inflammatory Bowel Diseases.
    Kochar B; Cai W; Cagan A; Ananthakrishnan AN
    Gastroenterology; 2020 Jun; 158(8):2104-2111.e2. PubMed ID: 32105728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis.
    Wang JL; Yin WJ; Zhou LY; Zhou G; Liu K; Hu C; Zuo XC; Wang YF
    Clin Rheumatol; 2020 Mar; 39(3):769-778. PubMed ID: 31823140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Association of Inflammatory Bowel Diseases with Autoimmune Disorders: A Report from the epi-IIRN.
    Bar Yehuda S; Axlerod R; Toker O; Zigman N; Goren I; Mourad V; Lederman N; Cohen N; Matz E; Dushnitzky D; Gavish M; Borovsky N; Schwarts D; Dotan I; Turner D
    J Crohns Colitis; 2019 Mar; 13(3):324-329. PubMed ID: 30304371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study.
    Li J; Liu Z; Hu P; Wen Z; Cao Q; Zou X; Chen Y; Wang Y; Zhong J; Shen X; Demuth D; Fadeeva O; Xie L; Chen J; Qian J
    BMC Gastroenterol; 2022 Feb; 22(1):44. PubMed ID: 35120446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease.
    Fiorino G; Allez M; Malesci A; Danese S
    Aliment Pharmacol Ther; 2009 May; 29(9):921-7. PubMed ID: 19210297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety Analysis of Preoperative Anti-TNF-α Therapy in Pediatric IBD After Intestinal Resection: A Systematic Review and Meta-analysis.
    Bajzát D; Kéri AF; Imrei M; Kói T; Párniczky A; Hegyi P; Kovács K; Váncsa S; Müller KE
    Inflamm Bowel Dis; 2023 Dec; 29(12):1971-1980. PubMed ID: 36789751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs.
    Na SY; Kim YS
    Korean J Intern Med; 2022 Sep; 37(5):906-919. PubMed ID: 35945034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence of Psoriasis in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Matched Cohort Study.
    Moon JM; Lee JY; Koh SJ; Park H; Kang S; Soh H; Lee HJ; Im JP; Kim JS
    Dermatology; 2021; 237(3):330-337. PubMed ID: 33556947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease.
    Kirchgesner J; Desai RJ; Beaugerie L; Schneeweiss S; Kim SC
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):314-324.e16. PubMed ID: 33387667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.